XOMAP NASDAQ
XOMA Royalty Corporation
1W: +0.0%
1M: +0.3%
3M: -4.4%
YTD: -7.9%
1Y: -0.4%
3Y: +22.3%
5Y: +36.5%
$24.98
Last traded 2026-07-21 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
39 relationships39
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-03-24
Earliest Filing
2026-02-09
Latest Filing
partner: 28
target: 7
acquirer: 2
licensee: 2
Counterparties (Filed by XOMAP)
39 relationshipsCompanies named in XOMAP's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Generation Bio Co. | — | target | Target company acquired in a merger transaction | 2026-02-09 | View |
| XRA 7 Corp. | — | partner | Wholly owned subsidiary of XOMA Royalty Corporation used as the merger subsidiary | 2026-02-09 | View |
| Broadridge Corporate Issuer Solutions, LLC | — | partner | Rights agent for the Contingent Value Rights Agreement | 2026-02-09 | View |
| LAVA Therapeutics N.V. | — | target | Target company acquired by XOMA Royalty Corporation in a share purchase and tender offer. | 2026-02-02 | View |
| Pfizer Inc. | PFE | partner | Partner holding an outlicensed agreement for the EGFRd2 (PF-8046052) legacy asset. | 2026-02-02 | View |
| Janssen Biotech, Inc. | — | partner | Partner holding an outlicensed research collaboration agreement for the JNJ-89853413 legacy asset. | 2026-02-02 | View |
| Mural Oncology plc | — | target | Target company acquired by XOMA Royalty Corporation via a scheme of arrangement. | 2025-12-05 | View |
| XRA 5 Corp. | — | partner | Wholly-owned subsidiary of XOMA Royalty Corporation used as the acquiring entity in the merger. | 2025-12-05 | View |
| Leerink Partners LLC | — | partner | Sales agent for Common Stock offering | 2025-10-03 | View |
| H.C. Wainwright & Co., LLC | — | partner | Sales agent for Preferred Stock offering | 2025-10-03 | View |
| HilleVax, Inc. | — | target | Target company acquired in a merger completed on September 17, 2025. | 2025-09-23 | View |
| XRA 4 Corp. | — | partner | Wholly owned subsidiary of XOMA Royalty Corporation used as the merger subsidiary. | 2025-09-23 | View |
| Turnstone Biologics Corp. | — | target | Target company acquired by XOMA Royalty Corporation via a merger and tender offer. | 2025-08-15 | View |
| XRA 3 Corp. | — | partner | Wholly owned subsidiary of XOMA that merged with Turnstone Biologics Corp. | 2025-08-15 | View |
| XRA 1 Corp. | — | acquirer | Wholly owned subsidiary of XOMA that merged with Kinnate Biopharma Inc. to complete the acquisition. | 2024-04-03 | View |
| Kinnate Biopharma Inc. | — | target | Target company acquired in a merger transaction where XOMA completed a tender offer and merged with its wholly-owned sub | 2024-04-03 | View |
| Kinnate Biopharma Inc. | KIN | target | Target company in a merger agreement to be acquired by XOMA Corporation via a cash tender offer and merger. | 2024-02-16 | View |
| Affitech | — | partner | Counterparty to Assignment Agreement and Commercial Payment Purchase Agreement | 2023-12-19 | View |
| Affitech Research AS | — | partner | Counterparty to Commercial Payment Purchase Agreement | 2023-12-19 | View |
| F. Hoffmann-La Roche Ltd | — | partner | Counterparty to Assignment Agreement | 2023-12-19 | View |
| Hoffman-La Roche Inc | — | partner | Counterparty to Assignment Agreement | 2023-12-19 | View |
| LadRx Corporation | LADX | partner | XOMA acquired rights to asset purchase agreement and royalties from LadRx | 2023-06-22 | View |
| Orphazyme ApS | — | partner | Original counterparty in the asset purchase agreement acquired by XOMA | 2023-06-22 | View |
| Zevra Denmark A/S | — | partner | Counterparty in the Zevra Agreement whose rights were assigned to XOMA | 2023-06-22 | View |
| ImmunityBio, Inc. | IBRX | partner | Counterparty in the Exclusive License Agreement whose milestone payments were acquired by XOMA | 2023-06-22 | View |
| Aptevo Therapeutics Inc. | APVO | partner | XOMA acquired deferred payment rights from Aptevo regarding sales of IXINITY marketed by Medexus. | 2023-03-30 | View |
| Medexus Pharma, Inc. | — | partner | Medexus markets IXINITY, the product whose sales generate the deferred payments acquired by XOMA. | 2023-03-30 | View |
| ObsEva, SA | — | acquirer | Swiss biotech company that sold rights to ebopiprant to XOMA | 2022-11-22 | View |
| Merck KGaA | MRK | licensee | Original licensor of ebopiprant to ObsEva | 2022-11-22 | View |
| Organon International GmbH | OGN | licensee | Holds a license agreement for ebopiprant development and commercialization | 2022-11-22 | View |
| Affitech Research AS | — | partner | XOMA purchased commercial payment rights to Roche's faricimab from Affitech for $6 million. | 2021-10-07 | View |
| Kuros Biosciences AG | — | partner | Partner in royalty purchase agreement for vidutolimod rights | 2021-07-20 | View |
| Kuros US LLC | — | partner | Partner in royalty purchase agreement for vidutolimod rights | 2021-07-20 | View |
| Kuros Royalty Fund (US) LLC | — | partner | Partner in royalty purchase agreement for vidutolimod rights | 2021-07-20 | View |
| Checkmate Pharmaceuticals | — | partner | Original licensor of vidutolimod (CMP-001) | 2021-07-20 | View |
| Affimed N.V. | AFMD | partner | Entered into a contractual arrangement with XOMA for payments on potential future commercial sales of ICE molecules and | 2021-04-16 | View |
| Viracta Therapeutics, Inc. | VIRX | partner | XOMA acquired rights to milestones and royalties for two drug candidates in exchange for an upfront payment. | 2021-03-24 | View |
| DOT Therapeutics-1, Inc. | — | partner | Developer of the clinical-stage drug candidate Day101. | 2021-03-24 | View |
| Denovo Biopharma LLC | — | partner | Developer of the clinical-stage drug candidate vosaroxin. | 2021-03-24 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-14 | Termination of Agreement; Acquisition/Disposition; Delisting Notice; Change in Control; Officer/Dire | Acquisition | View |
| 2026-06-12 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-22 | Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-05-18 | Material Agreement; Exhibits | Agreement | View |
| 2026-04-27 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-04-27 | Acquisition/Disposition; Other Events; Exhibits | Acquisition | View |
| 2026-03-02 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-02-09 | Completion of Acquisition or Disposition of Assets; Other Events; Financial Statements and Exhibits | Acquisition | View |
| 2026-02-02 | Completion of Acquisition or Disposition of Assets; Other Events; Financial Statements and Exhibits | Acquisition | View |
| 2026-01-15 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-05 | Completion of Acquisition or Disposition of Assets; Other Events; Financial Statements and Exhibits | Acquisition | View |
| 2025-11-21 | Completion of Acquisition or Disposition of Assets; Other Events; Financial Statements and Exhibits | Acquisition | View |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-03 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-09-26 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2025-09-23 | Completion of Acquisition or Disposition of Assets; Other Events; Financial Statements and Exhibits | Acquisition | View |
| 2025-08-15 | Completion of Acquisition or Disposition of Assets; Other Events; Financial Statements and Exhibits | Acquisition | View |
| 2025-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-30 | Material Modification to Rights of Security Holders; Departure/Election of Directors; Appointment of | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR